Exelixis Outlines Growth Strategy as CABOMETYX Franchise Reaches $2.12B, Zanzalintinib Launch by 2026
Source link
Rapid Micro Biosystems COO Wilson sells $17k of stock
Rapid Micro Biosystems COO Wilson sells $17k of stock Source link
Exelixis Outlines Growth Strategy as CABOMETYX Franchise Reaches $2.12B, Zanzalintinib Launch by 2026
Source link
Rapid Micro Biosystems COO Wilson sells $17k of stock Source link
Intact non-GAAP financial EPS of C$5.50 Source link